Amgen (NSDQ:AMGN) said today that it lowered the list prices of the drug-delivery devices for its cholesterol drug, Repatha, to $5,850 per year.
The Thousand Oaks, Calif.-based company touted the 60% discount as a way to boost patient affordability and accessibility.
Get the full story at our sister site, Drug Delivery Business News.